Dr. Singel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2008- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2004 - 2006
University of California San Diego School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2016 - 2025
TX State Medical License 2010 - 2017
WA State Medical License 2008 - 2011
Publications & Presentations
PubMed
- 19 citationsTransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cyt...David B Rosen, Anne Månsson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson
Journal for Immunotherapy of Cancer. 2022-07-01 - 98 citationsFAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancerMafalda Oliveira, Cristina Saura, P. Nuciforo, Isabel Calvo, Jay Andersen
Annals of Oncology. 2019-08-01 - 1403 citationsTrastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas
The New England Journal of Medicine. 2019-02-14
Press Mentions
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024September 13th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
